Drugs / PIMURUTAMAB
Trials 18 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05360368 | Mar → Dec 2023 | cancer | Shanghai Henlius Biotech | Unknown | No outcome recorded |
| Phase 1 | NCT02648490 | Sep 2016 → Jun 2019 | cancer | Henlix, Inc | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07358585 | Jan 2026 → Jul 2027 expected | colon adenocarcinoma | Shanghai Henlius Biotech | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT03577704 | Aug 2018 → Sep 2022 | cancer | Shanghai Henlius Biotech | Completed | No outcome recorded |
| Phase 212 trials | ||||||
| Phase 2 | NCT06857279 | Apr 2025 → Dec 2027 expected | head and neck carcinoma | Shanghai Henlius Biotech | Recruiting | No outcome recorded |
| Phase 2 | NCT06542588 | Jul 2024 → Dec 2025 overdue | rectal cancer | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Recruiting | No outcome recorded |
| Phase 2 | NCT05354700 | Mar 2023 → Mar 2024 | small cell lung carcinoma | Shanghai Henlius Biotech | Unknown | No outcome recorded |
| Phase 2 | NCT05215925 | Feb → Jul 2023 | neoplastic disease or syndrome | Shanghai Henlius Biotech | Unknown | No outcome recorded |
| Phase 2 | NCT05513573 | Dec 2022 → Sep 2024 overdue | nasopharyngeal carcinoma | Shanghai Henlius Biotech | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05221658 | Aug 2022 → Jun 2024 | digestive system carcinoma | Shanghai Henlius Biotech | Unknown | No outcome recorded |
| Phase 2 | NCT05290220 | Aug 2022 → Dec 2023 | hepatocellular carcinoma | Shanghai Henlius Biotech | Unknown | No outcome recorded |
| Phase 2 | NCT05239650 | Jul 2022 → Oct 2025 overdue | — | Shanghai Henlius Biotech | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05238363 | Jun 2022 → May 2023 | skin squamous cell carcinoma | Shanghai Henlius Biotech | Unknown | No outcome recorded |
| Phase 2 | NCT05246982 | Mar 2022 → Dec 2023 | gastric cancer | Shanghai Henlius Biotech | Unknown | No outcome recorded |
| Phase 2 | NCT04976647 | Jan 2022 → Jan 2023 | non-small cell squamous lung carcinoma | Shanghai Henlius Biotech | Unknown | No outcome recorded |
| Phase 2 | NCT04297995 | Jul 2020 → May 2024 | head and neck squamous cell carcinoma | Shanghai Henlius Biotech | Unknown | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT07459751 | May 2026 → Jan 2030 expected | non-small cell squamous lung carcinoma | Shanghai Henlius Biotech | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07318883 | Mar 2026 → Jan 2031 expected | non-small cell squamous lung carcinoma | Shanghai Henlius Biotech | Not yet recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PIMURUTAMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594549 ↗ |
| Known as | HLX07 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05238363 ↗ |
| Action | Inhibit | “Anti-EGFR” NCT05215925 ↗ |
| Modality | Monoclonal antibody | “HLX07 is an improved version of anti-EGFR monoclonal antibody.” NCT02648490 ↗ |
| Route | Intravenous | “HLX07 was administered weekly by 2-h intravenous infusion at doses ranging from 50 to 800 mg.” PMID 33713216 ↗ Mar 2021 |
| Target | EGFR | “recombinant human anti-EGFR monoclonal antibody against cancers” NCT02648490 ↗ |